Ceylon Cinnamon: Ancient Recognition, Now Verified by Modern Science

March 24, 2026

Written by Nalin Siriwardhana, PhD, FACN | Published by NUTRITUNES® Science of Supplements

01 · Background

Walk into almost any supermarket and pick up a jar labelled "cinnamon." The odds are strong that what is inside is not what most scientists mean when they say cinnamon in a clinical research context. This is not a minor labelling quirk — it is the central scientific problem with the cinnamon literature, and it has direct practical consequences for anyone choosing a supplement.

There are four commercially significant Cinnamomum species: C. verum (commonly called Ceylon or true cinnamon), C. cassia (Chinese cinnamon), C. loureiroi (Vietnamese or Saigon cinnamon), and C. burmannii (Indonesian or Korintje cinnamon). The names Cinnamomum verum and Cinnamomum zeylanicum refer to the same plant — both names appear in the scientific literature, with C. verum being the currently accepted botanical nomenclature. All four species are native to South and Southeast Asia. All four can be — and routinely are — labelled simply as "cinnamon" in commerce.

The practical issue is this: the four species differ substantially in their phytochemical composition, and they differ by orders of magnitude in one specific safety-relevant compound called coumarin. Understanding which species you are actually taking is the first and most important question to ask about any cinnamon supplement.

As for the historical context — historical records document cinnamon's presence in Egyptian ritual and embalming contexts by approximately 2000 BCE. It appears in the ancient Ayurvedic medical tradition, whose earliest texts are associated with compilations spanning several centuries BCE. Classical Greek physicians Dioscorides (~40–90 CE) and Galen (~130–210 CE) recorded its medicinal properties. The physician Ibn Sina (Avicenna, ~980–1037 CE) catalogued it in his Canon of Medicine. The Roman historian Pliny the Elder recorded in the first century AD that cinnamon was priced at approximately fifteen times its weight in silver.

Arab traders reportedly maintained deliberate secrecy about cinnamon's geographic origin for centuries — a commercial strategy that speaks to how valuable the source was considered. Three successive colonial empires (Portuguese, Dutch, then British) competed in sequence to control the island of Ceylon specifically because of its cinnamon. These are not the behaviours of civilisations pursuing a botanical with no perceived value.

That historical recognition is genuinely impressive. It does not, however, constitute evidence of pharmacological efficacy by modern scientific standards. What it does — legitimately — is establish that cinnamon drew the consistent attention of sophisticated medical traditions for a very long time, across cultures with no contact with each other. That convergence provides a well-documented rationale for the systematic scientific investigation that has followed over the past three decades — and it is that investigation which has begun to verify, qualify, and in some areas still test what those traditions observed.

02 · The Compounds

The bark of Cinnamomum verum contains a chemically complex mixture. The dominant volatile compound is trans-cinnamaldehyde — the molecule principally responsible for cinnamon's characteristic aroma. In C. verum bark essential oil, trans-cinnamaldehyde typically comprises approximately 50–70% of the volatile fraction, with higher concentrations reported in some studies depending on geographic origin and analytical method.

The bark is also associated with a class of polyphenols called Type-A proanthocyanidins (PAC-A), which have attracted research interest for their potential interactions with insulin signalling pathways. These represent a key standardisation target in several recent authenticated C. verum clinical studies.

One commonly encountered claim deserves a precision note: eugenol — a phenolic compound with antioxidant properties — is present at high concentrations in C. verumleaf oil (typically 70–90%), but is present at substantially lower concentrations in the bark oil used in supplementation (generally below 5% in most analyses). When evaluating any claim about cinnamon bark products and eugenol, this distinction matters.

Mechanistic research — conducted in cell cultures and animal models, not in humans — has described several biologically plausible molecular interactions. Cinnamaldehyde and PAC-A polyphenols have been shown in preclinical settings to inhibit alpha-glucosidase and alpha-amylase (enzymes involved in starch digestion), upregulate GLUT4 glucose transporter expression in skeletal muscle cells, activate the PI3K/Akt insulin-signalling cascade, and modulate NF-κB inflammatory pathways. These findings describe what the compounds appear to do in laboratory conditions. They establish biological plausibility — they are not evidence of what happens in a person taking a supplement.

03 · The Human Evidence

The honest starting point here is the position of the U.S. National Center for Complementary and Integrative Health (NCCIH), which is part of the National Institutes of Health. The NCCIH states plainly that many cinnamon studies are difficult to compare because the species or plant part used is often unclear, and that current evidence does not clearly support the use of cinnamon for any specific health condition. That statement is not dismissive of the research — it is a precise description of where the evidence currently sits, and it is why species-authenticated research matters so much.

A 2025 systematic review in Naunyn-Schmiedeberg's Archives of Pharmacology (Beheshti et al.) synthesised available in vitro, in vivo, and some clinical data on C. zeylanicum's metabolic properties, identifying a pattern of reported anti-diabetic, anti-dyslipidaemic, and anti-inflammatory activity across study designs — while emphasising that the majority of reviewed studies were preclinical, and that large-scale human trials are needed before definitive clinical conclusions can be drawn.

04 · The Safety Question

Here is the practical question that most supplement articles about cinnamon either miss entirely or bury: is the cinnamon you are taking safe to use regularly? The answer depends almost entirely on which species it is.

To put those numbers in practical terms: a single teaspoon of ground cassia cinnamon (approximately 2.6 g) may contain 7–20 mg of coumarin — placing typical daily cassia use at or around the EFSA Tolerable Daily Intake for a 70 kg adult. The German Federal Institute for Risk Assessment (BfR) has highlighted specific concern for children, whose lower body weight means proportionally higher coumarin exposure per gram of cinnamon consumed.

In a 60-sample retail analysis from Czech markets, cassia cinnamon samples ranged from 700 to over 7,000 mg/kg coumarin. The Sri Lankan C. verum sample in the same study registered below the analytical detection limit. This is not a marginal difference. It is the difference between a compound that is effectively absent and one that may exceed safety guidance in a single daily serving.

The naming problem makes this worse. A 2018 review in Clinical Pharmacology & Therapeutics (Oketch-Rabah, Marles, and Brinckmann) demonstrated directly that multiple cassia species are routinely sold and labelled as "cinnamon," making it difficult to interpret clinical research — or make safe choices — without confirmed species identity.

COUMARIN CONTENT BY SPECIES — ANALYTICAL DATA & REGULATORY CONTEXT

Sources: Blahová & Svobodová (2012), Scientific World Journal (PubMed 22593682) · EFSA Opinion on Coumarin (2004) · BfR Health Assessment No. 043/2006. Coumarin content varies by origin and analytical method.

ANCIENT RECOGNITION · MODERN VERIFICATION

Four evidence-based conclusions about what science has now confirmed — and what it is still testing

1.  Historical recognition was real — and science is now qualifying what it found. Independent civilisations across Egypt, Ayurveda, classical Greece, Rome, and the Arab world converged on the same botanical for overlapping purposes over two millennia. Modern phytochemistry has now identified the specific compounds present in the bark. What has been verified, what remains preliminary, and what is not yet established are detailed in the sections above.

2.  Human evidence is most developed for blood glucose — with important nuance. The best-designed species-authenticated trial to date (Muthukuda et al., 2025) found a statistically significant fasting blood glucose effect as a secondary outcome; the primary endpoint (LDL-C) was not met. Current evidence does not support using cinnamon to manage or treat any health condition. These findings should be interpreted within the context of study size, duration, and endpoint hierarchy. Larger confirmatory trials are needed.

3.  Species identity is the most important variable for both safety and evidence interpretation. Cassia cinnamon may contain coumarin at levels that approach or exceed the EFSA Tolerable Daily Intake in a single serving. Ceylon cinnamon (C. verum) has the lowest documented coumarin burden of any commercial species. Conclusions from cassia research cannot be applied to C. verum, or vice versa.

4.  For repeated use, C. verum is one of the most clearly characterised commercial cinnamon options. It combines the lowest documented coumarin burden, the most rigorous species-authenticated clinical research base, and the only EU Protected Geographical Indication among commercial cinnamon species. That combination is not currently matched by any other commercially available cinnamon species in regulatory or peer-reviewed literature.

SCIENTIFIC REFERENCES — ALL PUBMED-LINKED WHERE AVAILABLE

[1]  Encyclopaedia Britannica. Cinnamon (Cinnamomum verum). Secondary historical reference. Documents Egyptian use (~2000 BCE) and Pliny the Elder's silver valuation. britannica.com/plant/cinnamon  www.britannica.com

[2]  Rao PV & Gan SH. (2014). Cinnamon: A Multifaceted Medicinal Plant. Evidence-Based Complementary and Alternative Medicine 2014:642942. doi:10.1155/2014/642942. Review covering phytochemistry, antioxidant, anti-inflammatory, antidiabetic, and antimicrobial activities. PubMed PMID 24817901 · PMC4003790  PubMed · PMC

[3]  Beheshti AS, Qazvini MM, Abeq M, et al. (2025). Molecular, cellular, and metabolic insights of cinnamon (Cinnamomum zeylanicum) in diabetes and related complications. Naunyn-Schmiedeberg's Archives of Pharmacology 398(4):3513–3526. doi:10.1007/s00210-024-03644-0. Systematic review — majority of studies preclinical. PubMed PMID 39589531  PubMed

[4]  National Center for Complementary and Integrative Health (NCCIH). (2024). Cinnamon: Usefulness and Safety. U.S. National Institutes of Health. States evidence does not clearly support cinnamon for any specific health condition; documents species ambiguity and coumarin differential. nccih.nih.gov/health/cinnamon  www.nccih.nih.gov

[5]  Muthukuda D, de Silva CK, Ajanthan S, et al. (2025). Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults. PLoS ONE 20(1):e0317904. doi:10.1371/journal.pone.0317904. Species-authenticated RCT: primary endpoint (LDL-C) not met; secondary endpoint (fasting blood glucose) statistically significant. PubMed PMID 39854533 · PMC11759401  PubMed · PMC

[6]  Mohammadabadi T & Jain R. (2024). Cinnamon: a nutraceutical supplement for the cardiovascular system. Archives of Medical Sciences: Atherosclerotic Diseases 9:e72–e81. doi:10.5114/amsad/184245. Narrative review of mechanistic and preclinical cardiovascular literature. PubMed PMID 38846056 · PMC11155465  PubMed · PMC

[7]  Nakhaee S, Kooshki A, Hormozi A, Akbari A, Mehrpour O, Farrokhfall K. (2023). Cinnamon and cognitive function: a systematic review of preclinical and clinical studies. Nutritional Neuroscience 27(2):132–146. doi:10.1080/1028415X.2023.2166436. 40 studies: 33 animal, 5 in vitro, 2 human clinical trials. Human evidence insufficient for conclusions. PubMed PMID 36652384  PubMed

[8]  Yanakiev S. (2020). Effects of Cinnamon (Cinnamomum spp.) in Dentistry: A Review. Molecules 25(18):4184. doi:10.3390/molecules25184184. In vitro antimicrobial activity against oral pathogens; does not predict clinical outcomes. PubMed PMID 32932678 · PMC7571082  PubMed · PMC

[9]  European Food Safety Authority (EFSA). (2004). Opinion on Coumarin. EFSA Journal 2(9):104. doi:10.2903/j.efsa.2004.104. Establishes TDI: 0.1 mg coumarin/kg body weight/day. efsa.onlinelibrary.wiley.com  efsa.onlinelibrary.wiley.com

[10]  Blahová J & Svobodová Z. (2012). Assessment of Coumarin Levels in Ground Cinnamon Available in the Czech Retail Market. Scientific World Journal 2012:263851. doi:10.1100/2012/263851. 60-sample analysis: cassia 700–7,000+ mg/kg; C. verum below detection limit. PubMed PMID 22593682 · PMC3385612  PubMed · PMC

[11]  German Federal Institute for Risk Assessment (BfR). (2006). Coumarin in Cinnamon. Health Assessment No. 043/2006, 18 August 2006. Highlights children as a high-concern group for coumarin exposure from cinnamon products. bfr.bund.de — Health Assessment No. 043/2006  www.bfr.bund.de

[12]  Oketch-Rabah HA, Marles RJ, Brinckmann JA. (2018). Cinnamon and Cassia Nomenclature Confusion: A Challenge to the Applicability of Clinical Data. Clinical Pharmacology & Therapeutics 104(3):435–445. doi:10.1002/cpt.1162. Epub August 2018. PubMed PMID 29947417  PubMed

[13]  Department of Cinnamon Development, Government of Sri Lanka. (2023–2025). Official records documenting cinnamon cultivation to 1400 BCE; GI certification programme. cinnamon.gov.lk  cinnamon.gov.lk

[14]  European Union Commission. (2022). Implementing Regulation (EU) 2022/144. Registration of 'Ceylon Cinnamon' as EU Protected Geographical Indication — the first enforceable provenance standard for any commercial cinnamon species. eur-lex.europa.eu/eli/reg_impl/2022/144/oj/eng  eur-lex.europa.eu

Editorial Standards & Compliance: This article is part of the Nutritunes Science of Supplements series. No statements constitute health claims under EU Regulation 1924/2006, the U.S. DSHEA, or equivalent frameworks. Mechanistic and preclinical findings are explicitly distinguished from human clinical outcomes throughout. NCCIH is the primary balancing authority. EFSA and BfR documents provide the basis for all coumarin safety statements. The information reflects current scientific literature and may evolve as additional human clinical data becomes available. This content is not intended to replace professional medical advice, diagnosis, or treatment.